UCB's anti-tau Alzheimer's program fails Phase 2 primary endpoint, but highlights positive secondaries
UCB reported Thursday that a Phase 2 study for its anti-tau Alzheimer’s program bepranemab did not meet its primary endpoint.
Neither the low dose nor …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
